News about Clinical Trials

ISCR Urges Union Budget 2026 to Focus on Boosting India's Clinical Research Ecosystem

ISCR seeks higher funding, AI-led innovation and regulatory reforms in Union Budget 2026 to boost global competitiveness and accelerate patient access to therapies.

Clinical Trials | 17/01/2026 | By News Bureau

First Patient Dosed in New Beat AML Sub-Study Testing Triplet Therapy

Blood Cancer United launches a new Beat AML sub-study evaluating ficlatuzumab with venetoclax and azacitidine for newly diagnosed older adults with acute myeloid leukemia.

Clinical Trials | 15/01/2026 | By News Bureau

Boehringer Ingelheim Begins Phase IIa Trial of BI 765423 in IPF

Boehringer Ingelheim has initiated a Phase IIa clinical trial of BI 765423, a novel IL-11–targeting monoclonal antibody, in patients with Idiopathic Pulmonary Fibrosis (IPF), advancing its efforts to develop new treatment options for progressive fibrotic lung diseases.

Clinical Trials | 15/01/2026 | By News Bureau |  104

UK Sees Surge in Clinical Trials as MHRA Unveils Faster Approval Pathways

UK is boosting its global clinical trials appeal through rising trial activity and new fast-track MHRA regulations, enabling quicker approvals, earlier patient access and increased investment.

Clinical Trials | 14/01/2026 | By News Bureau |  114

First Patient Dosed in Phase III Tropian-Lung17 Trial of Datroway in Advanced NSCLC

The global Phase III study evaluates Datroway versus docetaxel in Trop2 NMR-positive advanced nonsquamous NSCLC patients previously treated with immunotherapy and platinum chemotherapy.

Clinical Trials | 14/01/2026 | By News Bureau

Nvidia and Eli Lilly Commit USD 1 Billion to AI-Driven Drug Discovery Lab

Nvidia and Eli Lilly and Company have announced plans to invest up to USD 1 billion over five years to establish a joint AI research laboratory focused on transforming drug discovery and pharmaceutical R&D.

Clinical Trials | 14/01/2026 | By Darshana

Thryv Therapeutics Initiates Wave II Phase II/III Trial for Long QT Syndrome Type 2

Thryv Therapeutics has launched the Wave II Phase II/III trial to evaluate THRV-1268, an oral SGK1 inhibitor, as a potential disease-modifying therapy for adults with Long QT Syndrome Type 2.

Clinical Trials | 14/01/2026 | By News Bureau

Clover Biopharmaceuticals Completes Initial Enrollment in Phase II Trial of RSV Combination Vaccines

The Australia-based Phase II study is evaluating Clover’s protein-based combination vaccine candidates SCB-1022 and SCB-1033 targeting RSV, hMPV and PIV3 in older adults, using its proprietary Trimer-Tag technology.

Clinical Trials | 12/01/2026 | By News Bureau |  101

Pfizer Reports Improved Response Rates with BRAFTOVI Regimen in Metastatic Colorectal Cancer

New data from the BREAKWATER study show that Pfizer’s BRAFTOVI-based regimen significantly improved response rates in patients with BRAF V600E–mutant metastatic colorectal cancer, supporting the potential use of flexible chemotherapy backbones.

Clinical Trials | 12/01/2026 | By News Bureau

Remedy Cell Launches Phase 1b Trial of RC-0315 in IPF

First-in-human study evaluates safety and tolerability of intra-bronchial RC-0315, a cell-derived therapy aimed at reducing fibrosis and restoring lung function in idiopathic pulmonary fibrosis patients.

Clinical Trials | 08/01/2026 | By News Bureau